Results 121 to 130 of about 5,867,860 (378)

IgD-secreting murine plasmacytomas: identification and partial characterization of two IgD myeloma proteins.

open access: yesJournal of Immunology, 1981
We have used an immunofluorescence inhibition assay to identify 2 BALB/c plasmacytomas, TEPC-1017 and TEPC-1033, that secrete large quantitites of IgD.
F. Finkelman   +3 more
semanticscholar   +1 more source

Inferring Gene Regulatory Networks From Single‐Cell RNA Sequencing Data by Dual‐Role Graph Contrastive Learning

open access: yesAdvanced Science, EarlyView.
RegGAIN is a novel and powerful deep learning framework for inferring gene regulatory networks (GRNs) from single‐cell RNA sequencing data. By integrating self‐supervised contrastive learning with dual‐role gene representations, it consistently outperforms existing methods in both accuracy and robustness.
Qiyuan Guan   +9 more
wiley   +1 more source

BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. [PDF]

open access: yes, 2016
The proteasome inhibitor MLN9708 is an orally administered drug that is hydrolyzed into its active form, MLN2238 (ixazomib). Compared with Bortezomib, MLN2238 has a shorter proteasome dissociation half-life and a lower incidence and severity of ...
Barkhouse, Darryll   +7 more
core   +2 more sources

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Selective molecular inhibition of the HDAC6 ZnF-UBP binding domain impairs multiple myeloma cell function

open access: yesCell Death Discovery
Multiple myeloma is a plasma cell malignancy with a poor prognosis despite the recent development of new therapeutic options. Histone deacetylase 6 (HDAC6) is overexpressed in multiple myeloma cells and may be involved in the acquisition of resistance to
Rafael Rincón   +8 more
doaj   +1 more source

Association of ABCB1 T-129C polymorphism and multiple myeloma risk in Polish population

open access: yesPolish Journal of Pathology, 2019
The possible interaction between gene polymorphism and cancer risk development is a very interesting issue. The genetic variants of the ATP-binding cassette superfamily B member 1 (ABCB1) are known to be involved in developing cancer risk and individual ...
Katarzyna Niebudek   +3 more
doaj   +1 more source

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity. [PDF]

open access: yesEur J Haematol, 2022
Heaney JLJ   +12 more
europepmc   +1 more source

GENETIC CHARACTERS OF HUMAN γ-GLOBULINS IN MYELOMA PROTEINS

open access: yesJournal of Experimental Medicine, 1962
The genetic factors Gm(a), Gm(b), Gm(x), and Inv(a), Inv(b) described for normal human γ-globulin were all found in different myeloma proteins. A single myeloma protein never contained more than one product of alternate alleles even in heterozygous ...
M. Harboe   +3 more
semanticscholar   +1 more source

Tumor Extracellular Vesicles lncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A‐Dependent hnRNPA2B1/COX‐2 Axis

open access: yesAdvanced Science, EarlyView.
Tumor‐derived extracellular vesicles program inflammatory lung premetastatic niches through selective delivery of long noncoding RNAs. This work reveals EVs‐associated lncOSLMT as a key driver of lung fibroblast activation via m6A‐dependent PTGS2 stabilization.
Hongbo Li   +10 more
wiley   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

open access: yes, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M   +6 more
core   +2 more sources

Home - About - Disclaimer - Privacy